Connect Biopharma Holdings Ltd
Research Connect Biopharma Holdings Ltd (CNTB) on Bullrun: market cap USD 54.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCNTB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 54.79M
- Financial periodQ2 2026
- RevenueUSD 2.77M
- Net income-USD 17.28M
- Free cash flow-USD 15.92M
Valuation Snapshot
latest market cap is USD 54.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 64.00K | -USD 55.48M | -USD 51.64M | n/a | -1 | USD 38.35M | USD 690.00K | USD 41.98M |
| FY2024 | USD 26.03M | -USD 15.63M | -USD 24.36M | n/a | -0.28 | USD 78.23M | USD 178.00K | USD 92.17M |
| FY2023 | USD 0 | -USD 62.11M | -USD 47.82M | n/a | -1.13 | USD 105.66M | USD 465.00K | USD 101.50M |
| FY2022 | USD 0 | -USD 118.09M | -USD 105.93M | n/a | -12.2 | USD 79.01M | USD 431.00K | USD 157.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 54.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 159.17M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 76.38M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 64.98M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 47.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 283.64M | n/a | n/a | n/a |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Connect Biopharma Holdings Ltd's market cap?
Connect Biopharma Holdings Ltd's market capitalization is USD 54.79M.
What does Connect Biopharma Holdings Ltd do?
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.